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Abstract
Background: We evaluated whether tumor infiltrating lymphocytes (TIL) could be expanded from surgically
resected tumors from pancreatic cancer patients.
Methods: Tumors were resected from pancreatic cancer patients. Tumors were minced into fragments and
cultured in media containing high dose interleukin-2 (IL-2) for up to 6 weeks. T cell phenotype, activation markers,
and reactivity were measured.
Results: TIL expansion was measured in 19 patient samples. The majority of these TIL were CD4+ T cells and were
highly activated. Purified CD8+ T cells produced IFN-γ in response to HLA-matched pancreatic tumor targets. PD-1
blockade and 4-1BB stimulation were demonstrated as effective strategies to improve effective TIL yield, including
the production of tumor-reactive pancreatic TIL.
Conclusions: TIL expanded from pancreatic tumors are functional and able to respond to pancreatic tumor
associated antigens. PD-1 blockade, 41BB stimulation, and CD8+ T cell enrichment are effective strategies to
improve TIL yield and tumor reactivity. These results support the development of adoptive cell therapy strategies
using TIL for the treatment of pancreatic cancer.
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Background
Pancreatic adenocarcinoma is the fourth-leading cause
of cancer-related mortality in the United States. Patients
diagnosed with this disease face a 5-year survival rate of
less than 5 %, and the only available treatments, surgery,
chemotherapy and chemoradiation, have shown limited
effectiveness [1, 2]. Only a small fraction (20 %) of these
patients are even eligible for surgery with curative intent,
and most will develop recurrent disease within 2 years
of definitive therapy [3]. Therefore, alternative treatment
strategies are urgently needed.
Recent successes in immunotherapy for the treatment
of metastatic melanoma have resulted in its application to
other types of cancer. Specifically, adoptive cell therapy
(ACT) is a particularly promising approach that utilizes
endogenous tumor-infiltrating lymphocytes (TIL), which
are expanded in vitro from a surgically resected tumor
and then re-infused back into the patient. This therapy for
metastatic melanoma patients is associated with a 20 %
complete response lasting beyond 3 years [4]. In patients
with gastrointestinal (GI) tumors, infiltration of CD3+ T
cells is associated with a higher rate of progression free
survival [5], and pancreatic adenocarcinomas containing
both CD4+ and CD8+ T cells correlated with an improved
prognosis and significantly greater 5-year survival for
these patients [6–8]. Therefore, there is evidence of a host
T cell immune response in patients with pancreatic adeno-
carcinoma, supporting the potential application of ACT
using TIL for this cancer histology.
Correspondingly, there is no shortage of studies demon-
strating that the tumor microenvironment of pancreatic
adenocarcinoma is inherently immunosuppressive, with a
vast array of mechanisms to escape immune surveillance.
These include co-inhibitory ligands, such as PDL1 and
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PDL2, which directly interact with T cells to dampen their
effector response [9–12], regulatory T cells [13–17], re-
duced antigen presentation [18], and suppressive cyto-
kines [19–21]. Additionally, activated TIL upregulate
checkpoint molecules such as PD-1, which may serve to
dull the intensity of the inflammatory response and induce
tolerance toward tumor antigens [22].
Despite all of these factors, TIL expanded in vitro to
large numbers have the potential to be reprogrammed as
effectors of a productive anti-tumor response [4]. In fact,
it has recently been demonstrated that PD-1+ TIL repre-
sent the repertoire of clonally expanded tumor-reactive
cells in melanoma [23]. Identifying and targeting enriched,
tumor-specific TIL subsets in vitro and in vivo is an active
area of research intended to augment TIL growth and
function in order to improve the efficacy of ACT.
In the present study, we successfully expanded TIL from
19 patients with pancreatic adenocarcinoma in the presence
of high dose IL-2. The majority of these TIL were CD4+ T
cells and were highly activated. Both PD-1 blockade
and 4-1BB agonism led to improved TIL yields. Enrich-
ment of CD8+ T cells was an effective strategy to measure
tumor-reactive pancreatic TIL. These results support the
use of TIL expanded from pancreatic tumors in ACT
strategies for patients with pancreatic adenocarcinoma.
Results
Pancreatic TIL are predominantly CD4
In order to establish the feasibility of isolating and
expanding TIL from pancreatic adenocarcinomas, we
adapted our previous experience with melanoma to es-
tablish pancreatic TIL cultures [24]. Tumors were surgi-
cally resected from 20 different patients with pancreatic
cancer at the Moffitt Cancer Center and used to set up
tumor fragment cultures for the isolation and propaga-
tion of TIL. Of note, the volume of tumor received in
the laboratory after pathological analysis was consider-
ably smaller compared to those typically obtained to
derive melanoma TIL. This resulted in an average of
14.3 tumor fragments from resected pancreatic cancer
specimens from which TIL were initially propagated,
compared to over 48 fragments from a typical melanoma
resection. Despite this, TIL were successfully isolated
from at least one plated fragment in 19 of the 20 patient
tumors (95 %) in the presence of high dose IL-2
(6000 IU/mL) after 3 to 6 weeks of culture (Table 1 and
Additional file 1: Table S1) and were predominantly
CD4+ T cells. TIL yield varied between patient samples
with an average yield of 1.79x107 TIL from an average of
just over 14 fragments per patient. Four samples of the 17
(23.5 %) measured gave rise to at least 25 million TIL, the
minimum number required for initiation of a clinical scale
rapid expansion protocol (REP). Extrapolated to the 48
fragments typically set up during a clinical scale expansion,
the average yield increased to over 83 million TIL, with
nine of 17 (52.9 %) samples meeting the REP initiation
threshold. The majority of these expanded TIL were CD4+
(66.1 ± 21.0 %), while CD8+ T cells comprised a mean of
25.6 ± 17.0 % (Fig. 1a). The remaining analyzed CD3+ TIL
not within these single positive gates were predominantly
double negative cells. Importantly, pancreatic TIL were
also capable of REP, the second phase of pre-infusion TIL
growth. Three patient samples were subjected to the full,
two week REP which resulted in an average fold expansion
of 964 (Additional file 1: Table S2), which compared simi-
larly to our experience in melanoma TIL where ~1000 fold
expansion is observed during the REP. Twelve additional
samples underwent an 8 day mini-REP and exhibited a 93-
fold expansion on average over that time (n = 12, data not
shown). This data demonstrate that generating sufficient
TIL for adoptive cell therapy from pancreatic adenocarcin-
oma fragments is possible given the procurement of ad-
equately sized specimens needed to yield the high numbers
of TIL required to initiate the REP.
Pancreatic TIL have an activated phenotype
To characterize the phenotype of these expanded pan-
creatic TIL, we examined the expression of markers in-
volved in the activation, differentiation and function of
T cells. Since the majority of TIL were CD4+, we investi-
gated the presence of regulatory T cells (Tregs) by intracel-
lular staining for FOXP3 on the CD4+CD25+ population.
We found that the frequency of CD4+CD25+FOXP3+ Tregs
is quite low (~4 %) in expanded pancreatic TIL as a
proportion of the total CD3+ population (Fig. 1b). TIL
were nearly entirely CD45RO+ CCR7−, characteristic of
antigen-experienced effector T cells (data not shown). Ap-
proximately 50 % of CD8+ cells and 40 % of CD4+ cells
expressed CD69 (Fig. 1c i), indicating an efficient and sus-
tained T cell stimulation [25]. TIL also exhibited a low
level of CD27 expression (Fig. 1c ii), a marker known to
be down-regulated as T cells approach terminal differenti-
ation [26]. We further characterized the phenotype of
these cultured TIL and found that more than 40 % of
CD8+ cells expressed the co-stimulatory marker CD28
(Fig. 1c iii) and more than 20 % cells expressed GITR
(Fig. 1c iv), a receptor crucial for the proliferation of acti-
vated CD8+ T cells [27]. Additionally, less than 5 % of TIL
were 4-1BB+, a co-stimulatory marker that is expressed on
activated T cells after TCR engagement (Fig. 1c v) [28]. IL-
2 receptor alpha (CD25), which is up-regulated after TCR
stimulation, was expressed in greater than 30 % of CD4+
TIL and 20 % of CD8+ TIL (Fig. 1c vi) [29]. Data for each
of these phenotypic markers can be found in Additional
file 1: Table S1 on a per patient basis. Notably, as evalu-
ated on a small cohort of samples, these phenotypic indi-
cators of activation were largely unchanged, showing
no significant difference through the two-week REP
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(Additional file 1: Figure S2). Overall, pancreatic
adenocarcinoma TIL that were successfully expanded
from tumor fragments were found to express numer-
ous markers of activation and antigen experience and
were comprised of a low frequency of Tregs.
PD-1 blockade increases expansion of pancreatic TIL
In addition to the above phenotypic markers, we also
stained for the presence of PD-1 on pancreatic TIL. PD-1 is
a co-inhibitory receptor that restricts T cell activity and has
recently been shown to be specifically present on tumor-
reactive TIL [23, 30]. TIL from digested tumor samples an-
alyzed by flow cytometry displayed relatively high levels of
PD-1, as over 30 % of CD4+ TIL (38.2 ± 22.1 %) and 40 %
of CD8+ TIL (45.7 ± 26.8 %) were positive for surface PD-1
(Fig. 2a). In contrast, the level of PD-1 expression was low
on expanded pancreatic TIL, with a frequency of 4.8 % for
CD4+ T cells and 6.9 % for CD8+ T cells (Fig. 2b).
The detection of PD-1 expression on freshly isolated
TIL prompted an investigation of whether the blockade
of PD-1 inhibitory signaling in early culture could affect
the outcome of pancreatic TIL growth. An antagonistic
PD-1 antibody was added at the initiation of TIL culture
to determine its effect on TIL propagation from pancre-
atic tumors. This was compared to culture of TIL in the
presence of an isotype control antibody. Addition of the
isotype antibody had no effect on TIL expansion (data
not shown). The absolute number of TIL from three
patients dramatically increased after PD-1 blockade (2.5
fold), while frequency of cell death in comparison to the
isotype control was unchanged (Fig. 2c, d). Pancreatic
TIL cultured in the presence of anti-PD-1 antibody from
a single patient produced significantly more IFN-γ in
the presence of a HLA-matched pancreatic tumor line
as compared to TIL cultured with an isotype control
(Additional file 1: Figure S1). These data suggested that
the inhibition of PD-1 signaling can augment the propaga-
tion of pancreatic TIL from tumor fragments and increase
the expansion of pancreatic tumor-specific T cells.
Targeting 4-1BB increases expansion of pancreatic TIL
Similarly, the effect of an agonistic 4-1BB antibody on
TIL growth was determined through its addition during
TIL expansion. In digested pancreatic tumor samples,
10.8 % of CD4+ TIL and 7.9 % of CD8+ TIL expressed
4-1BB (Fig. 3a). Tumor fragments were cultured in IL-2
Table 1 TILs from Pancreatic Adenocarcinoma are Predominantly CD4+
Patient CD4+ CD8+ Fragments plated TIL yield Yield per 48 fragments
1 31.8 54.3 4 4.97E + 05 5.96E + 06
2 95.4 4.04 9 1.40E + 08 7.47E + 08
3 96.9 1.90 24 1.13E + 07 2.26E + 07
4 96.6 1.34 24 6.40E + 05 1.28E + 06
5 64.0 33.5 23 3.78E + 07 7.89E + 07
6 72.0 21.7 24 2.52E + 07 5.04E + 07
7 60.2 33.0 33 5.32E + 06 7.74E + 06
8 74.5 22.8 12 1.42E + 06 5.68E + 06
9 92.1 5.79 36 3.64E + 07 4.85E + 07
10 41.3 46.5 10 5.90E + 06 2.83E + 07
11 a a 9 N/A N/A
12 52.4 34.4 24 ND ND
13 85.1 12.6 1 2.92E + 06 1.40E + 08
14 49.9 17.9 12 1.80E + 06 7.20E + 06
15 36.9 49.5 5 1.34E + 06 1.29E + 07
16 55.8 38.6 2 6.90E + 05 1.66E + 07
17 60.1 24.2 1 ND ND
18 67.9 28.7 7 2.37E + 07 1.63E + 08
19 80.7 9.02 14 1.89E + 06 4.68E + 07
20 41.6 47.1 12 7.50E + 06 7.50E + 06
Mean 66.1 25.6 14.3 1.79E + 07 8.31E + 07
SD 21.0 17.0 10.5
All TIL analyzed are pre-Rapid Expansion Protocol (REP)
a TIL growth not observed; N/A not applicable, ND no data
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in the presence or absence of anti-4-1BB antibody. On a
per fragment basis, both the absolute TIL yield and the
number of CD3+CD8+ lymphocytes were significantly
augmented in the 4-1BB treated group when compared
to the isotype control. Overall, a 3.5-fold expansion was
measured (Fig. 3b), while a 23-fold difference in the
CD8+ TIL resulted from the addition of agonistic 4-1BB
(Fig. 3c). These results support the targeting of 4-1BB as
a strategy to selectively expand CD8+ T cells from pan-
creatic tumors, which have been shown to be essential
to the anti-tumor response [31].
Functional potential of pancreatic TIL
To investigate whether these expanded pancreatic TIL
are capable of responding to extracellular stimulation,
TIL were stimulated with PMA and ionomycin. After
18 h, we observed a clear increase in surface expression
of CD107a, which is associated with degranulation and
cytotoxic activity of T cells, and accumulated intracellu-
lar IFN-γ, an important effector of the TIL anti-tumor
response [32, 33]. We found that more than 50 % of
CD8+ pancreatic TIL were positive for IFN-γ expression,
and greater than 70 % of CD8+ TIL were capable of pro-
ducing either CD107a or IFN-γ (Fig. 4a, b). Under these
same conditions, greater than 80 % of melanoma TIL
were able to present IFN-γ (data not shown). These data
suggest that expanded pancreatic TIL contain the func-
tional potential to elicit an anti-tumor response.
As reported above, the majority (66 %) of expanded
pancreatic TIL were found to be CD4+ (Fig. 1a). Al-
though these T cells were capable of producing IFN-γ at
a similar level to CD8+ TIL in response to stimulation
Fig. 1 Characterization of pancreatic TIL after expansion. a Expanded pancreatic TIL were characterized phenotypically by flow cytometry for CD4
and CD8 expression on CD3+ lymphocytes (mean % ± SD). n = 19 (b) TIL were surface stained with CD3, CD4, CD8, and CD25, then further
characterized by intracellular staining with Foxp3. Data are reported as mean % ± SD. p < 0.0001 as determined by Wilcoxon matched pairs
signed rank test. n = 19. c TIL were additionally surface stained for markers of activation and antigen experience CD69 (i, n = 17), CD27 (ii, n = 11),
CD28 (iii, n = 11), GITR (iv, n = 8), 4-1BB (v, n = 18), and CD25 (vi, n = 19) on CD4+ and CD8+ cells within the CD3+ lymphocyte population.
Summary data are reported as mean % ± SD
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(Fig. 4b), the tumor-specific immune response is thought
to be mediated primarily by CD8+ cells [34]. To help de-
fine the function of CD8+ pancreatic TIL, we enriched
CD8+ cells from whole TIL by depletion of CD4+ cells.
The remaining CD8+ TIL were then expanded following
the mini-REP, as diagrammed in Fig. 5a. Selective expan-
sion of CD8+ T cells in the mini-REP prevented their dilu-
tion by CD4+ T cells, and allowed an increased opportunity
to capture CD8+ T cell tumor reactivity through a co-
culture assay. The CD8+ TIL were enriched from 19 % to
67 % and remained predominantly CD8+ throughout this
substantial expansion (Fig. 5b). Furthermore, these post-
REP CD8+ TIL retained their effector capacity in response
to stimulation with PMA and ionomycin (Fig. 5c), as the
majority of TIL expressed intracellular IFN-γ and nearly
one third were CD107a+.
CD8+ pancreatic TIL are tumor specific
To further evaluate whether pancreatic TIL have tumor
specificity, CD8+ post-REP TIL were cultured with HLA-
matched pancreatic cell lines. The amount of IFN-γ re-
leased in co-culture was measured after 48 h. Pancreatic
TIL from two individual patients produced significantly
more IFN-γ in the presence of HLA-matched pancreatic
tumor lines as compared to HLA-mismatched tumor
(Fig. 6a, b). This data demonstrates that tumor-reactive
CD8+ T cells are present within the repertoire of pancre-
atic TIL and are functional against shared pancreatic
tumor antigens in an HLA-dependent manner.
Discussion
The development of novel therapeutic approaches for
pancreatic adenocarcinoma is paramount to the successful
Fig. 2 PD-1 inhibition yields increased pancreatic TIL. a Expression of PD-1 on TIL in digested pancreatic tumor samples was measured by flow
cytometry. Representative data shown in flow plots as well as summary data of mean ± SD (n = 4). b After expansion, TIL were surface stained for
CD3, CD4, CD8, and PD-1 and analyzed for PD-1 expression on CD3+ CD4+ or CD3+ CD8+ lymphocytes. Data are reported as mean % ± SD
(n = 16). Pancreatic TIL were then propagated from fragments of pancreatic adenocarcinoma specimens in 6000 IU/mL rhIL-2 in the presence of
10 μg/mL α-PD-1 or the isotype control (IgG) antibody. After 2 weeks, total TIL were counted (c), and assessed for viability (d). Fold change was
normalized to the isotype control. Column graph displays mean values with positive SD shown. Percentages present the corresponding frequency
in the PD-1 or control group (n = 3 patients). Statistical significance was determined by the Wilcoxon signed rank test
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treatment and recovery from this aggressive cancer. In the
age of personalized cancer medicine, adoptive cell therapy
(ACT) using tumor-infiltrating lymphocytes (TIL) repre-
sents a unique opportunity to exploit both the diversity
and specificity of a patient’s immune system. The CD8+ T
cells within this population represent an endogenous poly-
clonal repertoire of TCRs specific and comprehensive for
the array of tumor-associated antigens (TAAs) and unique
neoantigens present [35]. Within the appropriate set-
ting, these infiltrates are capable effectors of a targeted
anti-tumor response that can be both durable and
complete [4].
In the present study, we explored the feasibility of
expanding TIL from resected pancreatic adenocarcin-
omas. ACT is dependent upon both the quantity and
quality of the lymphocytes recovered from the original
source. Importantly, we showed that TIL can be ex-
panded from surgically resected pancreatic tumors and
REP’d to clinically relevant metrics. Given the inherent
constraint of only one in every five patients with pancre-
atic cancer as a candidate for surgery for curative intent,
it is significant that nearly all of the tumors in this study
contained lymphocytes capable of in vitro propagation.
In addition, a recent study has also demonstrated the
feasibility of expanding functional TIL from pancreatic
tumor samples [36].
Excess (not required for pathologic analysis), surgically
resected pancreatic adenocarcinomas received in the la-
boratory for TIL generation were characteristically small
in size, restricting the supply of starting material crucial
to culturing TIL from tumor fragments. It has previously
been reported that the density of infiltrating lympho-
cytes is also inferior in GI tumors when compared to
melanoma, leading to an increased time required for ex-
pansion [28]. These drawbacks are important to consider
given that one central concern of ACT is the necessary
delay between surgery and infusion. Pretreatment of pa-
tients, such as with immune checkpoint inhibitor ther-
apies, prior to surgical resection in order to enrich
tumors for specific lymphocyte populations should be
investigated as a means to overcome this limitation.
T cells localized to the pancreatic tumor microenvir-
onment have long been characterized as both intrinsic-
ally and extrinsically suppressed, frequently attributed to
the presence of Tregs [14, 37, 38]. Importantly, in the
current study after expansion in IL-2, pancreatic TIL
were predominantly activated T cells, before and after
REP, and presented markers of antigen experience, in-
cluding CD69 and CD45RO. Furthermore, we demon-
strated that high doses of IL-2 in vitro did not polarize
the pancreatic TIL cultures toward a Treg phenotype, but
may have influenced the observed activated phenotype.
A relatively high Teff to Treg ratio was established, which
is thought to be critical for effective immunosurveillance
of tumors [37, 38]. This result highlights the importance
of releasing pancreatic TIL from their naturally inhibi-
tory tumor microenvironment and supports the notion
that pancreatic TIL have a plastic phenotype that can be
polarized toward an effector function. Therefore, our
data on pancreatic TIL support previous reports that
TIL from GI tumors resemble the activated state of TIL
derived from melanomas [28].
Fig. 3 Addition of 4-1BB agonist improves yield of CD8+ pancreatic TIL. a Pancreatic tumor digests were assessed for 4-1BB expression by flow
cytometry. The data represent mean + SD (n = 3). Separately, fragments of pancreatic tumors were initially plated in TIL CM containing 6000 I.U./
mL IL-2 and 10 ug/mL anti-4-1BB antibody or IgG4 isotype control. TIL were subsequently cultured according to standard techniques, with the
addition of 1 ug/mL anti-4-1BB or isotype. b Viable TIL were counted by trypan blue exclusion after pre-REP expansion and reported as a fold
change over isotype control for each patient total (n = 3 patients). Significance was determined by the Wilcoxon signed rank test. c Pancreatic TIL
were then analyzed by flow cytometry for CD3, CD4, CD8 expression on live lymphocytes. Absolute numbers were derived from cell counts and
percentages based on FACS analysis on a per fragment basis. Statistical significance was determined by the Mann-Whitney Test (n = 3 patients).
Data are reported as mean % ± SD
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We found that the inhibitory molecule PD-1 was
expressed at substantial levels on minimally cultured
pancreatic TIL, within the range of PD-1 expression re-
ported on TIL from other GI tumors [28]. The presence
of PD-1, which is thought to be preferentially expressed
on a comprehensive repertoire of tumor-reactive TIL,
confirmed that these T cells were antigen-experienced
and demonstrated the need to isolate these TIL from po-
tential sources of ligand inhibition [23, 30]. Moreover,
we were able to capitalize on the surface expression of
PD-1 through the addition of a blocking antibody to the
TIL culture and observed a substantial increase in the
expansion of TIL. This data suggest that disrupting PD-1
signaling during ex vivo TIL culture may selectively ex-
pand tumor-reactive T cells, but this requires further
investigation before any conclusions can be drawn.
Additionally, PD-1 expression on TIL is known to be
transient during culture with IL-2, as we also observed
(Fig. 2b), potentially highlighting the limited window to
employ this strategy for augmenting TIL growth [30].
We also investigated the effects of an agonistic 4-1BB
antibody on its ability to improve the yield of pancreatic
TIL as we have previously observed this in TIL derived
from melanoma [39]. TIL expanded in media supple-
mented with anti-4-1BB demonstrated a significant in-
crease in the absolute number of TIL produced on a per
fragment basis. Furthermore, these TIL were predomin-
antly CD8+ T cells with a 32-fold difference in yield of
this population compared to control cultures. As 4-1BB
positive TIL are thought to correspond to those T cells
undergoing recent TCR engagement, it is possible that
this selective expansion of CD8+ lymphocytes represents
Fig. 4 Stimulated pancreatic TIL display effector function. a Propagated TIL were stimulated with 25 ng/mL of PMA and 500 nM ionomycin for
18 h, then stained for CD3, CD4, CD8, and CD107a or the corresponding isotype antibodies followed by intracellular staining for IFN-γ and
analyzed by flow cytometry. All cells stained with the isotype control were stimulated under the same conditions. Representative FACS plots
gated on CD3+ CD8+ TIL are shown. b Scatter plots display the percentage of each indicated population for individual patient data. Each analysis
refers to the percentage of IFN-gamma (IFN-g) + and/or CD107a + cells within the CD4 or CD8 gates of the CD3+ lymphocytes. Error bars
represent mean % ± SD (n = 12)
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the population of tumor resident TIL specific for
expressed tumor antigens on the surface of pancreatic
adenocarcinoma [28].
It is widely accepted that CD8+ T cells are instrumen-
tal for an anti-tumor response, but the involvement of
CD4+ T cells is far less clear and potentially disruptive
[31, 40, 41]. In one murine study, the presence of TNFα
and IL-17-producing CD4+ T cells in pancreatic cancer
was associated with relatively aggressive disease [42]. For
this reason, we chose to isolate the CD8+ pancreatic TIL
to use as effectors in tumor reactivity assays. A major
difficulty for the translation of TIL therapy into pancreatic
patients is the lack of autologous tumor for the evaluation
of tumor-specific reactivity. This required a reliance on
HLA-matched pancreatic tumor lines, known for their
relative lack of shared antigens, as TIL targets [35]. Im-
portantly, we were able to demonstrate a significant and
specific, HLA restricted immune response to matched
tumor targets using this strategy. Previous studies have
shown that an immune response toward shared pancreatic
cancer antigens can be elicited, and our results confirm
that TIL expanded from pancreatic tumors are functional
when re-stimulated with HLA-matched tumor targets
[7, 13, 43–48]. A recent study demonstrated that TIL
expanded from pancreatic tumors recognized shared pan-
creatic tumor antigens, including NY-ESO-1, survivin, and
mesothelin [36]. While reactivity to shared antigens can
be measured in a subset of pancreatic TIL samples, it has
been shown that patient with metastatic GI malignancies
have unique mutations, and anti-tumor T cell responses
are targeted to neoantigens specific to each individual pa-
tient [35]. Moving forward, it will be important to develop
effective methods to establish autologous tumor targets.
This would also allow for more complete evaluation of the
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Fig. 5 CD8+ pancreatic TIL maintain effector function after selective expansion. a CD8+ T cells were enriched through magnetic depletion of CD4+
cells from bulk TIL and subject to the rapid expansion protocol (REP). b Representative FACS plots of CD3+ TIL were analyzed for CD4
and CD8 expression before and after the procedure described in a. c CD8-enriched TIL were then stimulated with 25 ng/mL of PMA and
500 nM ionomycin and analyzed for surface CD107a and intracellular IFN-gamma (IFN-g) by flow cytometry
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TIL compartment, including CD4+ TIL, which have
been previously demonstrated to recognize autologous
tumor [41].
Conclusions
TIL were readily isolated and expanded from pancreatic
tumors and characterized by a predominantly activated
phenotype, rather than the suppressor phenotype previ-
ously reported to be present in the tumor microenviron-
ment. The ability of pancreatic TIL to react to tumor
antigen stimulation indicates that this population has
the capacity to effect a tumor-specific response. There-
fore, ACT with TIL is a therapeutic strategy that should
be further investigated for pancreatic adenocarcinoma, a
cancer with high lethality and limited treatment options.
Methods
TIL culture
Pancreatic tumors were minced into ~1 mm3 fragments,
placed in 24 well plates with 2 mL of TIL media contain-
ing IL-2, and pancreatic TIL were allowed to extravasate
from the tissue. If available, excess tissue was physically
and enzymatically digested as described below. Alterna-
tively, 48 well plates were used following the same
procedure, using 1 mL of TIL media and IL-2. TIL were
expanded in vitro for 3–6 weeks in 6000 I.U./mL IL-2
(Proleukin, Novartis, Emeryville, CA) per mL of
complete TIL media (TIL-CM) consisting of RPMI 1640,
2.05 mM L–glutamine (HyClone, Thermo Fisher Scien-
tific, Waltham, MA), 10 % heat-inactivated human AB
serum (Omega Scientific, Tarzana, CA), 55 μM 2-
mercaptoethanol (Invitrogen), 50 μg/mL gentamicin
(Invitogen), 100 I.U./mL penicillin, 100 μg/mL strepto-
mycin, and 10 mM HEPES Buffer (Mediatech, Manassas,
VA) in 24 or 48 well plates. Half of the media was re-
placed every 2 to 3 days or wells were split when 80 %
confluent. For TIL generation in the presence of costi-
mulatory antibodies, TIL were propagated as above with
the addition of an antagonistic human PD-1 antibody
(Nivolumab, 10 μg/mL) or with an agonistic human
4-1BB antibody (Urelumab, 10 μg/mL at initiation,
followed by continued supplement with 1 μg/mL at each
feeding or splitting as above) generously provided by Drs.
Alan Korman and Maria Jure-Kunkel (Bristol Myers
Squibb, Princeton, NJ).
Rapid expansion protocol (REP)
In a GREX10 flask (Wilson Wolf ), 5.0 × 105 pancreatic
TIL were stimulated with 30 ng/mL human anti-CD3
(OKT3, Ortho Pharmaceutical, Raritan, NJ) in the pres-
ence of 1.0 × 108 irradiated (5000 rad) allogenic PBMC
feeder cells. TIL were cultured in 20 mL of 50 % REP
Media I (described below) and 50 % AIM V (Invitrogen)

































Fig. 6 Pancreatic TIL produced tumor specific immune response. CD8-enriched post-REP TIL from two patients were cultured with HLA-matched
(in black) or mismatched (in gray) pancreatic cancer cell lines at a 1:1 ratio. a The patient was HLA-A typed as A01/24 and matched with the
MiaPaca-2 (A24) cell line, and mismatched with the Panc-1 (A02/11) pancreatic tumor cell lines. b The patient was HLA-A typed as A02/24 and
matched with the CFPAC-1 (A02/03) and Panc-1 (A02/11) pancreatic tumor cell lines, and mismatched with HPAFII (A01/11) tumor cell line. IFN-
gamma levels in supernatants were measured after 48 h and reported as mean ± SEM and statistical significance was determined by the student’s
t-test. *, p < 0.05, **, p < 0.01, ***, p < 0.001
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10 mL of the same media was added to the GREX flask.
On day 7, cultures were counted and split as necessary
and the remaining volume in the flask was filled with
AIM V media supplemented with 3000 I.U./mL rhIL-2.
After 14 days, TIL were collected and counted and
rested in pre-REP culture conditions prior to future
analysis.
Mini rapid expansion protocol (mini-REP)
In a T25 flask, 1.43 × 105 pancreatic TIL were stimulated
with 30 ng/mL human anti-CD3 (OKT3, Ortho Pharma-
ceutical, Raritan, NJ) in the presence of 2.9 × 107 irradi-
ated (5000 rad) allogenic PBMC feeder cells. TIL were
cultured in REP Media I comprised of RPMI 1640,
2.05 mM L–glutamine (HyClone, Thermo Fisher Scien-
tific), 10 % heat-inactivated human AB serum (Omega
Scientific), 55 μM 2-mercaptoethanol (Invitrogen), and
10 mM HEPES Buffer (Mediatech). On day 5, 70 % of
the media was replaced with REP Media II comprised of
a 1:1 (v:v) mixture of REP Media I and AIM V (Invitro-
gen). Media was supplemented with 6000 I.U./mL rhIL-
2 on days 2 and 5 of the 8 day REP. This protocol was
also implemented in T75 flasks at exactly triple the
aforementioned cell counts and reagents.
Expansion of CD8+ TIL
CD8+ T cells were enriched from propagated TIL by
depletion of CD4+ cells with a human CD8+ isolation kit
(Miltenyi Biotech, Germany) according to the manufac-
turer’s protocol. CD8+ TIL were expanded for 8 days
using a mini-REP in T25 flasks.
Flow cytometry
Excess tumor tissues not used for TIL generation were
digested physically using scalpels and enzymatically with
media containing collagenase type IV (1 mg/mL), DNase
type IV (30 U/mL), and hyaluronidase type V (100 μg/mL)
(Sigma). Single cell suspensions were strained and counted
via trypan blue exclusion, followed by cryopreservation for
future analysis. Tumor digests and TIL were stained at
varying points in the expansion process using the follow-
ing: APC, PE, FITC, PECy7, PerCpCy5.5, and Alexa-
Fluor700 conjugated antibodies: CD3, CD4, CD8, CD25,
FoxP3, CD69, PD-1, GITR, 4-1BB, CTLA-4, CCR7,
CD45RO, CD27, CD28, and CD122 (BD Biosciences, San
Jose, CA; , eBioscience, La Jolla, CA; or R&D Systems,
Minneapolis, MN). All panels contained the LIVE/DEAD
Aqua or LIVE/DEAD Near-IR dead cell stain (Invitrogen).
Intracellular Foxp3 staining was carried out in accordance
with the manufacturer’s protocol (eBioscience). Data were
acquired on an LSRII flow cytometer (BD Biosciences)
and analyzed using FlowJo software (TreeStar, Inc.).
CD107a and IFN-γ functional assay
A flow cytometry-based analysis of TIL function was de-
signed to detect CD107a membrane expression and
intracellular IFN-γ expression. Briefly, TIL were stimu-
lated at 37 °C overnight at a concentration of 5 × 105
cells/mL in the presence of 25 ng/mL phorbol myristate
acetate (PMA) and 0.5 μM ionomycin. After 90 min of
stimulation, APC conjugated CD107a or its IgG1 k isotype
(BD Biosciences) were added. Brefeldin A, at 1 μg/mL,
(Sigma Aldrich) and monensin, at 0.067 % (v/v), (Golgi-
Stop, BD Biosciences) were added one hour later. After
18 h, cells were washed once with Staining Buffer (PBS
containing 0.05 % (v/v) Human AB serum), then surface
stained (4 °C for 30 min.) with AlexaFluor 700, PECy7,
and PerCpCy5.5 conjugated anti-CD3, CD4, and CD8
(BD Biosciences), respectively. The LIVE/DEAD Aqua
(Invitrogen) dye was included as a cell viability stain.
Cells were washed once with Staining Buffer and then
fixed and permeabilized with BD Cytofix/Cytoperm for
20 min at 4 °C and washed twice with BD Perm/Wash
(BD Biosciences). Intracellular staining of FITC conju-
gated anti-IFN-γ (BD Biosciences) occurred at 4 °C for
30 min, followed by one wash with BD Perm/Wash.
Cells were stored in 0.5 % paraformaldehyde (Thermo
Fisher Scientific) at 4 °C in the dark. All samples were run
on an LSRII flow cytometer (BD Biosciences) within 48 h
and analyzed using FlowJo software (TreeStar, Inc.)
Co-culture assays
Effector TIL were co-cultured in TIL CM in round-
bottom 96-well plates (5 × 104 TIL) at a 1:1 ratio with
pancreatic cancer cell line targets for 24 or 48 h. Cell
lines MiaPaca-2, Panc-1, CFPAC-1, and HPAF-II were
obtained from the ATCC and cultured according to the
manufacturer’s guidelines. Supernatants were collected
and reactivity of pancreatic TIL to HLA-matched pan-
creatic cancer cell lines was determined following the
manufacturer’s instructions for the IFN-γ ELISA assay
(Human IFN-γ Quantikine ELISA Kit, R&D Systems).
Optical density of each well was measured at 450 nm
and IFN-γ concentration was calculated from the stand-
ard curve.
Viability analysis
TIL were counted and assessed for viability using the
Guava ViaCount Reagent and ViaCount software accord-
ing to the manufacturer’s instructions and analyzed on
the Guava PCA system (Guava Technologies, Hayward,
CA). Alternatively, TIL were counted by trypan blue ex-
clusion on a hemocytometer.
Statistical analysis
Data represented as scatter plots show individual patient
data points or fragments where indicated as well as error
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bars representing mean values and the standard devi-
ation (SD) or standard error of the mean (SEM). P
values were determined using GraphPad Prism software
by the paired, two-tailed t-test, Wilcoxon signed rank
test, Mann Whitney test, or unpaired Student’s t-test
where indicated.
Additional file
Additional file 1: Figure S1. Pancreatic TIL cultured in the presence of
PD-1 blocking antibody demonstrated increased tumor reactivity. TIL
expanded with anti-PD-1 or the isotype control were co-cultured with
HLA-A matched (black) and mismatched (empty) tumor lines. IFN-gamma
release was assessed by ELISA after 24 h and reported as mean ± SD
(n = 1). Figure S2. Pre-REP and Post-REP Pancreatic TIL are phenotypically
similar. Pancreatic TIL were expanded from fragments in IL-2, then
subjected to the full, two week REP. TIL were stained for the indicated
surface markers, in addition to CD3, CD4, CD8, and a viability dye.
Data represent percentage positive of the parent gate CD4 (A) or
CD8 (B) as a mean ± SD (n = 3). (PPTX 285 kb)
Abbreviations
ACT: Adoptive cell therapy; GI: Gastrointestinal; PMA: Phorbol myristate
acetate; REP: Rapid expansion protocol; SD: Standard deviation;
SEM: Standard error of the mean; TIL: Tumor infiltrating lymphocytes
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